HQL - Tekla Life Sciences Investors

NYSE - NYSE Delayed Price. Currency in USD
16.06
+0.30 (+1.90%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close15.76
Open15.78
Bid16.06 x 1000
Ask16.72 x 800
Day's Range15.78 - 16.12
52 Week Range13.95 - 20.68
Volume106,143
Avg. Volume72,768
Market Cap365.457M
Beta (3Y Monthly)1.26
PE Ratio (TTM)39.27
EPS (TTM)0.41
Earnings DateN/A
Forward Dividend & Yield1.48 (9.39%)
Ex-Dividend Date2019-05-30
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire

    Tekla Life Sciences Investors Declares Stock Distribution

    On August 16, 2019, Tekla Life Sciences Investors declared a stock distribution of $0.37 per share. The record date for the stock distribution is August 28, 2019 and the payable date is September 30, 2019. This stock distribution will automatically be paid in newly issued shares of the Fund unless otherwise instructed by the shareholder.

  • Business Wire

    Tekla Healthcare Opportunities Fund Paid Distribution

    On July 31, 2019, Tekla Healthcare Opportunities Fund paid a monthly distribution of $0.1125 per share. It is currently estimated that this distribution is derived from return of capital or other capital source.

  • Business Wire

    Tekla World Healthcare Fund Paid Distribution

    On July 31, 2019, Tekla World Healthcare Fund paid a monthly distribution of $0.1167 per share. It is currently estimated that this distribution is derived from return of capital or other capital source.

  • Business Wire

    Tekla Healthcare Investors Paid Distribution

    On June 28, 2019, Tekla Healthcare Investors paid a distribution of $0.45 per share. It is currently estimated that this distribution is derived from return of capital or other capital source.

  • Business Wire

    Tekla Life Sciences Investors Paid Distribution

    On June 28, 2019, Tekla Life Sciences Investors paid a distribution of $0.37 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains and return of capital or other capital source.

  • Business Wire

    Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program

    Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-year period ending July 14, 2019. The renewal will allow the Fund to purchase in the open market up to 12% of its outstanding common shares for a one year-period ending July 14, 2020.

  • MoneyShow

    Top Picks 2019- Tekla Life Sciences Investors HQL

    For more conservative investors, my top income pick for the coming year is Tekla Life Sciences Investors (HQL), a closed-end fund, explains Nate Pile, editor of Nate's Notes and a specialist in healthcare and biotechnology stocks.